Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods.

October 19, 2016 at 8:04 am

Front Microbiol. 2016 Jun 13;7:895.

Lee CR1, Lee JH1, Park KS1, Kim YB2, Jeong BC1, Lee SH1.

Author information

1National Leading Research Laboratory of Drug Resistance Proteomics, Department of Biological Sciences, Myongji University Yongin, South Korea.

2Division of STEM, North Shore Community College, Danvers MA, USA.

Abstract

The emergence of carbapenem-resistant Gram-negative pathogens poses a serious threat to public health worldwide.

In particular, the increasing prevalence of carbapenem-resistant Klebsiella pneumoniae is a major source of concern.

K. pneumoniae carbapenemases (KPCs) and carbapenemases of the oxacillinase-48 (OXA-48) type have been reported worldwide.

New Delhi metallo-β-lactamase (NDM) carbapenemases were originally identified in Sweden in 2008 and have spread worldwide rapidly.

In this review, we summarize the epidemiology of K. pneumoniae producing three carbapenemases (KPCs, NDMs, and OXA-48-like).

Although the prevalence of each resistant strain varies geographically, K. pneumoniae producing KPCs, NDMs, and OXA-48-like carbapenemases have become rapidly disseminated.

In addition, we used recently published molecular and genetic studies to analyze the mechanisms by which these three carbapenemases, and major K. pneumoniae clones, such as ST258 and ST11, have become globally prevalent.

Because carbapenemase-producing K. pneumoniae are often resistant to most β-lactam antibiotics and many other non-β-lactam molecules, the therapeutic options available to treat infection with these strains are limited to colistin, polymyxin B, fosfomycin, tigecycline, and selected aminoglycosides.

Although, combination therapy has been recommended for the treatment of severe carbapenemase-producing K. pneumoniae infections, the clinical evidence for this strategy is currently limited, and more accurate randomized controlled trials will be required to establish the most effective treatment regimen.

Moreover, because rapid and accurate identification of the carbapenemase type found in K. pneumoniae may be difficult to achieve through phenotypic antibiotic susceptibility tests, novel molecular detection techniques are currently being developed.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904035/pdf/fmicb-07-00895.pdf

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Biología Molecular, Epidemiología, Health Care-Associated Infections, HIC no SIDA, Infecciones emergentes, Metodos diagnosticos, Resistencia bacteriana, REVIEWS, Sepsis, Update. Tags: .

Recurrent complicated urinary tract infection due to rare pathogen Sphingomonas paucimobilis: contamination or real deal? Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis.


Calendar

October 2016
M T W T F S S
« Sep   Nov »
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Most Recent Posts


%d bloggers like this: